News - Abraxane

Filter

Current filters:

Abraxane

Popular Filters

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

18-01-2014

US biotech firm Celgene’s breast cancer drug, Abraxane (nanoparticle albumin-bound paclitaxel), has…

AbraxaneBiotechnologyCelgeneOncologyResearchSpecialised Therapeutics Australia

NantBioScience enters cancer collaboration with Celgene

NantBioScience enters cancer collaboration with Celgene

14-01-2014

USA-based NantBioScience, a subsidiary of privately-held NantWorks, has entered into a strategic collaboration…

AbraxaneBiotechnologyCelgeneLicensingNantBioSciencesNTB-010NTB-011OncologyResearch

Celgene’s Abraxane given European approval for pancreatic cancer

Celgene’s Abraxane given European approval for pancreatic cancer

07-01-2014

US biotech company Celgene’s European subsidiary today announced that the European Commission has granted…

AbraxaneCelgeneEuropeOncologyPharmaceuticalRegulation

Celgene’s Abraxane gets positive CHMP opinion for pancreatic cancer

Celgene’s Abraxane gets positive CHMP opinion for pancreatic cancer

29-11-2013

US biotech company Celgene’s (Nasdaq: CELG) European subsidiary has received a positive opinion from…

AbraxaneCelgeneEuropeOncologyPharmaceuticalRegulation

Abraxane shows increased survival in metastatic pancreatic cancer

Abraxane shows increased survival in metastatic pancreatic cancer

17-10-2013

Celgene International, a wholly-owned subsidiary of Celgene Corp, has announced the results of the MPACT…

AbraxaneCelgeneNorth AmericaOncologyPharmaceuticalResearch

US FDA backs Abraxane for metastatic pancreatic cancer

09-09-2013

US biotech firm Celgene (Nasdaq: CELG) said on Friday (September 6) that the US Food and Drug Administration…

AbraxaneBiotechnologyCelgenegemcitabine HclNorth AmericaOncologyRegulation

Celgene's Abraxane plus gemcitabine extends survival in pancreatic cancer patients

23-01-2013

US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III clinical trial of Abraxane (nab-paclitaxel)…

AbraxaneBiotechnologyCelgenegemcitabine HclOncologyResearch

TGen, Scottsdale Healthcare study Abraxane combo for pancreatic cancer

20-11-2012

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage…

AbraxaneBiotechnologyCelgeneOncologyResearch

Celgene's Abraxane meets primary endpoints in pancreatic cancer study

13-11-2012

In what was some good news on the pancreatic cancer scene, the European subsidiary of US biotech firm…

AbraxaneBiotechnologyCelgeneOncologyResearch

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Celgene's Abraxane meets main goal in melanoma trial; reviews nanomedicines

04-10-2012

Celgene International Sarl, a subsidiary of the USA's Celgene Corp (Nasdaq: CELG) has announced results…

AbraxaneBiotechnologyCelgeneOncologyPharmaceuticalResearch

Back to top